ExploreInterventionvenlafaxine and lithium
Intervention

venlafaxine and lithium

Also known as: Continuation ECT (STABLE algorithm) plus venlafaxine and lithium over 6 months Continuation ECT (STABLE algorithm: 4 fixed weekly sessions then symptom-driven flexible ECT, right unilateral ultrabrief pulse) plus venlafaxine 225mg/day and lithium (0.4-0.6 mEq/L) over 6 months Continuation ECT (STABLE algorithm: mean 4.5 +/- 2.5 sessions over 6 months, right unilateral ultrabrief pulse) plus venlafaxine and lithium VEN Li
12 findings 1 paper 9 related entities View in graph →

Related entities

interventions
conditions
outcomes
populations
studys

Findings (50)

None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher mental component scores on the SF-36 over 6 months compared to those receiving medications alone, with an 8.2-

Effect: improvement; 8.2 point advantage (MCS); CI: 95% CI 4.2-12.2

Size: 8.2 point advantage (MCS) CI: 95% CI 4.2-12.2
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4
None
improvement

Elderly MDD patients receiving continuation ECT plus medications had significantly higher physical component scores on the SF-36 over 6 months compared to those receiving medications alone, with a 7-p

Effect: improvement; 7 point advantage (PCS); CI: 95% CI 3.5-10.4

Size: 7 point advantage (PCS) CI: 95% CI 3.5-10.4

Papers (1)